NCT01056276 · REGISTRY CONDITION SEARCH

Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2017-05-03

In this study, investigators will evaluate the activity of bendamustine, bortezomib and dexamethasone (BBD). This regimen combines 3 agents with high activity in multiple myeloma, with different mechanisms of action and non-overlapping toxicities.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Complete Response Rate

→

outcome · POSTED

Number of Patients Who Experienced Serious and Non-serious Adverse Events

→

outcome · POSTED

Progression Free Survival

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Overall Response Rate

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: 1. Patients must meet the Durie and Salmon criteria for initial diagnosis of multiple myeloma. 2. Previously histologically confirmed, multiple myeloma with indication for therapy including one of the following: * Hemoglobin \<10 g/dl or 2 g/dl below normal * Serum calcium \>11.5 mg/dl * Creatinine \>2 mg/dl * Lytic bone lesions or severe osteopenia * Extramedullary plasmacytomas 3. Patients should not be considered candidates for high dose therapy/autologous stem cell transplantation due to coexistent medical conditions, advanced age, poor performance status, refusal of high dose chemotherapy, or other reasons as judged by the patient and/or physician. 4. ECOG Performance Status 0-2. 5. WBC ≥3000/mL; ANC ≥1000/mL; platelets ≥50,000/mL (patients with platelets ≥30,000/mL are eligible if thrombocytopenia is felt to be due to extensive bone marrow involvement with myeloma). 6. Patients with adequate organ function as measured by: Renal: Serum creatinine \<2.0 mg/dL or a calculated or measured creatinine clearance of \>30 mL/minute. Hepatic: Total bilirubin \< 1.5 x ULN and ALT and AST \<2.5 x the ULN (\<5 x ULN for patients with liver involvement). 7. Patients must have measurable or evaluable disease. In patients with disease limited to bone and bone marrow, serial paraprotein measurements are acceptable for evaluable disease. 8. Patients must be accessible for treatment and follow-up procedures. 9. Male or female patients 18 years of age or older. 10. Patients must provide written informed consent prior to receiving protocol therapy. 11. Women of childbearing potential must agree to use a medically acceptable method of birth control(e.g., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and for 12 months after their last dose of rituximab. Men must use an acceptable form/method of contraception for the duration of treatment and for 3 months after the end of treatment. 12. Patients must be able to understand the nature of this study and give written informed consent. Exclusion Criteria: 1. Previous therapy for multiple myeloma with the exception of an initial 4-day course of pulsed dexamethasone. 2. Patients with ≥NCI CTCAE v4.0 grade 2 peripheral neuropathy ≤14 days prior to study enrollment. 3. Treatment with investigational agent(s) ≤14 days prior to study enrollment. 4. Active infection or infection requiring intravenous antibiotic treatment at the time of accrual. 5. Known to be HIV positive (HIV test is not required for participation in the trial). 6. Patients with class III/IV cardiac problems as defined by the New York Heart Association (NYHA)criteria: * History of uncontrolled or symptomatic angina * History of arrhythmias requiring medications, or clinically significant, with the exception of asymptomatic atrial fibrillation requiring anticoagulation * Myocardial infarction \< 6 months from study entry * Uncontrolled or symptomatic congestive heart failure * Ejection fraction below the institutional normal limit * Any other cardiac condition that, in the opinion of the treatment physician, would make this protocol unreasonably hazardous for the patient * Uncontrolled hypertension (systolic blood pressure \[BP\] \>180 or diastolic BP \>100mm Hg)or uncontrolled cardiac arrhythmias. * Prior to study entry, any ECG abnormality at Screening must be documented by the investigator as not medically relevant. 7. Other serious medical conditions or psychiatric illness that would potentially interfere with patient participation in this trial. 8. A second malignancy, other than basal cell carcinoma of the skin or in situ carcinoma of the cervix,unless the tumor was treated with curative intent at least 2 years previously or low-risk prostate cancer after curative therapy. 9. Known hypersensitivity to bortezomib, boron, or mannitol. 10. Female patient is pregnant or lactating. Confirmation that female patients of childbearing potential are not pregnant must be established by a negative serum pregnancy test ≤7 days prior to start of treatment.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Bendamustine, Bortezomib,and Dexamethasone for 8 cycles or 2 cycles beyond a confirmed complete response, assessed by IMWG criteria. Patients with stable disease and no intolerable toxicity may continue maintenance therapy with Bortezomib and Dexamethasone until disease progression or intolerable toxicity.
intervention Names
Drug: Bendamustine
Drug: Bortezomib
Drug: Dexamethasone
label
Treatment
type
EXPERIMENTAL

interventions

arm Group Labels
Treatment
description
Treatment: 80 mg/m2 via intravenous (IV) Days 1 and 2; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.
name
Bendamustine
other Names
Treanda
type
DRUG
arm Group Labels
Treatment
description
1.3 mg/m2 IV Days 1, 8, 15; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response. Maintenance: 1.3 mg/m2 IV or SQ Days 1, 15
name
Bortezomib
other Names
Velcade
type
DRUG
arm Group Labels
Treatment
description
20 mg orally (PO) Days 1, 2, 8, 9, 15, 16 every 28-days for 8 cycles or 2 cycles beyond confirmed complete response, Maintenance: 20 mg PO Days 1, 15
name
Dexamethasone
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 59
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Defined as the percent of patients having a complete response (CR) to treatment, assessed using the International Myeloma Working Group (IMWG) Uniform Response Criteria. CR=disappearance of soft tissue plasmacytomas and 5% or less plasma cells in bone marrow.
measure
Complete Response Rate
time Frame
every 8 weeks for approximately 48 months
description
All serious adverse events (SAEs) and non-serious adverse events (AEs) were assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0, and were collected from start of study treatment until 30 days after last dose of study medication. Refer to the Adverse Event module for specific terms.
measure
Number of Patients Who Experienced Serious and Non-serious Adverse Events
time Frame
approximately 36 weeks

secondary Outcomes

description
Defined as the interval of time (in months) that patient are alive from date of first protocol treatment to date of documented tumor progression or date of death from any cause. Progressive disease, assessed according to International Myeloma Working Group Uniform Response Criteria, is defined as at least a 25% increase from the nadir in any one of the following criteria: serum M-protein, urine M-protein, or bone marrow plasma cell percentage of 10% or greater.
measure
Progression Free Survival
time Frame
every 8 weeks for up to 48 months
description
Defined as the interval of time, in months, from first study treatment until the earlier of the date of death or date last known alive.
measure
Overall Survival
time Frame
every 4 weeks until progressive disease then every 12 weeks, projected 48 months
description
The number of patients with observed complete or partial response (CR or PR) assessed by International Myeloma Working Group (IMWG) Uniform Response Criteria. PR=50% or greater reduction from baseline in serum M-protein and 90% or greater reduction from baseline in 24-hour urinary M-protein.
measure
Overall Response Rate
time Frame
every 4 weeks for approximately 2 years

Full study description

brief Summary: In this study, investigators will evaluate the activity of bendamustine, bortezomib and dexamethasone (BBD). This regimen combines 3 agents with high activity in multiple myeloma, with different mechanisms of action and non-overlapping toxicities.
detailed Description: The purpose of this study is to assess the efficacy, tolerability, and toxicity of bendamustine, bortezomib, and dexamethasone (BBD) as first-line treatment of multiple myeloma (MM) patients who are transplant ineligible or who are not candidates for high dose chemotherapy. Eligible patients will receive protocol treatment for up to 34 weeks plus the screening period (up to 2 weeks). Response assessments will occur every 4 weeks and confirmed using the International Myeloma Working Group Uniform Response Criteria. Patients having an objective response or stable disease will continue to maintenance therapy until disease progression or intolerable toxicity.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-d7a30548d5ca43f87f71
requested nct id
NCT01056276
primary nct id
NCT01056276
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
5a5011fbc174a969e3e3bba6b9c90bb9ebfd0e688646ffd25570abac30d8f949
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-d7a30548d5ca43f87f71
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01056276
occurrences
context exact
NCT01056276
end
11
exact text
NCT01056276
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/305/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
4e1a4739497da8d5d65cb6db784bd6067cc0b765582bbb952eacc85f7be73980
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice